Basic↦Drug or Device↦Therapeutic Products↦Good Manufacturing Practice
What is it? Why is it important?
Good Manufacturing Practice (GMP) describe processes that ensure that:
- Therapeutic Products (TP) are produced in a consistent manner.
- Production procedures with its quality standards, are subject to ongoing quality controls with respect to the TP`s intended use
- The management of product defects and complaints of authorised Medicinal Products (MP) works in a feedback loop manner
Processes must be clearly defined, reviewed for applicability, and diligently documented. The ongoing documentation during TP production is paramount in order to prove to Regulatory Authorities (RA) (e.g. Swissmedic) that production and quality standards were complied with. Swissmedic inspects TP production sites in the context of a TP marketing approval application.
Personnel responsible for the production and quality assurance must:
- Comply with the required GMP standards
- Have the required skills and trainings
Once approved by Swissmedic, Good Distribution Practices (GDP) come into effect (access additional information under "More")
More
Compliance with Good Distribution Practices (GDP) ensure that the Medical Product (MP):
- Supply chain is authorised in accordance with RA legislations (e.g. Swissmedic, EU)
- Is transported and stored according to defined requirements (e.g. acceptable timelines, temperature, light and humidity exposure, vibration and access protected)
- Is protected against contamination by other products
- Reaches the right addressee
- Has an adequate turnover
MP distributors should have an effective tracing system in place, enabling finding faulty MP products including the implementation of required recall procedures.
GDP also address the sourcing, storage and transportation of active pharmaceutical ingredients and other ingredients used in the production of MPs.
What do I need to do?
As a SP-INV and Site-INV, make yourself familiar with GMP and GDP guidelines and their applicability and requirements during study planning and conduct, such as:
- GMP requirements in the production of a placebo product used in an interventional blinded study
- Transport, storage and access requirements of a Medical Product (MP)
- Documentation needed to confirm compliance with GMP and GDP requirements
Note: The “Drug & Device” section addresses Medicinal Products and Medical Devices. “In Vitro Medical Devices” are not discussed in the Easy-GCS.
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
External Links
Swissmedic – see in particular
- Human medicines / licensing / authorisation / Certificates
- Latest news / general communication / access Consortium statement
References
ICH GCP E6(R3) – see in particular guidelines and glossary
- 11. Investigational products should be manufactured in accordance with GMP standards
- 3.15.2 Manufacturing, packaging, labelling, coding
- Glossary: Investigational product definition
Swiss Law
TPA – see in particular articles
- Art. 4 Medicinal Product (MP) definition
- Art. 4 Distribution / dispensing definition
- Art. 7 Manufacturing standards (GMP)
- Art. 29 Wholesale standards (GDP)
- Art. 58 Official market surveillance
MPLO Medicinal Products Licensing Ordinance – see in particular articles
- Art. 1 Object and definitions
- Art. 4 Responsibility and GMP
- Art. 13 Market release